Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Changing Negative Cash Mentalities: Enabling Your Monetary Excursion - 2Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
- 3A definitive Manual for the 5 Off-road Bicycles Available
- 4Investigating the World's Chief Authentic Urban communities to Visit
- 5Step into Nature: A Survey of \Handling Trails with Solace\ Climbing Shoes
- Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- 5 Home Improvement Styles: Decision in favor of Your #1
- New research reveals urban raccoons across the US show early signs of domestication
- Gauging the Upsides and downsides of Visas: A Complete Aide
- Wait, it's 'Harry Potter and the Philosopher's Stone'? Why the new HBO series name is significant to Americans
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- Scientists reveal earliest evidence for shifting of Earth’s crust
- Smoking rate among US adults drops to record low as vape use rises, CDC report finds
- ‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
